Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study

This publication has 25 references indexed in Scilit:

• Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study
  Clinical Microbiology and Infection, 2021
• IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
  Journal of Allergy and Clinical Immunology, 2021
• Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019
  Chest, 2020
• Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
  Science, 2020
• A minimal common outcome measure set for COVID-19 clinical research
  The Lancet Infectious Diseases, 2020
• Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration
  2020
• Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
  Autoimmunity Reviews, 2020
• Effective treatment of severe COVID-19 patients with tocilizumab
  Proceedings of the National Academy of Sciences, 2020
• COVID-19: consider cytokine storm syndromes and immunosuppression
  The Lancet, 2020
• Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
  Rheumatology, 2010